48% shorter mean length of stay among those treated compared with those not treated (P<0.001) 51% fewer readmissions compared with the pre-intervention period (P<0.001) 33% fewer instances of return to… Read More
VANCOUVER, BC — SignalChem Lifesciences Corp. today announced that it has received a No Objection Letter (NOL) from Health Canada for its clinical trial “A Single-Arm, Open-Label, Phase 1b/2 Study… Read More
KIRKLAND, QC — The National Advisory Committee on Immunization (NACI) has provided a strong recommendation for PREVNAR 20 for the following adult populations who have not been previously immunized with… Read More
VANCOUVER, BC — (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that… Read More
Research hubs will further strengthen Canada’s biomanufacturing and life sciences sector while protecting Canadians against future health threats The Government of Canada’s main priority continues to be protecting the health… Read More
